Delayed cerebral ischemia (DCI) is one of the major causes of a poor neurological outcome following aneurysmal subarachnoid hemorrhage (aSAH). Several biomarkers, including matrix metalloproteinase-9 (MMP-9), have been evaluated to predict the development of DCI for timely management. This prospective cohort study was done on 98 patients with aSAH presenting within 72 h of the ictus. Serum samples were collected preoperatively, 7 days after ictus, 10 days after ictus, or when the patient developed DCI, whichever was earlier. The primary objective was to correlate the serum MMP-9 levels with the development of DCI. The secondary objectives were to correlate the serum MMP-9 levels with sonographic vasospasm and the neurological outcome. There was no correlation between the serum MMP-9 levels and the development of DCI (p = 0.37). Similarly, there was no correlation between the serum MMP-9 levels and the sonographic vasospasm (0.05) nor with the modified Rankin Scale (mRS) at discharge (p = 0.27), mRS at 3 months (p = 0.22), and Glasgow Outcome Scale Extended (GOSE) at 3 months (p = 0.15). Serum MMP-9 levels do not predict the development of DCI following aSAH.

迟发性脑缺血（DCI）是动脉瘤性蛛网膜下腔出血（aSAH）后神经功能不良的主要原因之一。包括基质金属蛋白酶 9 (MMP-9) 在内的多种生物标志物已被评估，可预测 DCI 的发展，以便及时进行治疗。这项前瞻性队列研究针对 98 名在发作后 72 小时内出现的 aSAH 患者进行。术前、发作后 7 天、发作后 10 天或患者出现 DCI 时（以较早者为准）收集血清样本。主要目的是将血清 MMP-9 水平与 DCI 的发展相关联。次要目标是将血清 MMP-9 水平与超声血管痉挛和神经系统结果相关联。血清 MMP-9 水平与 DCI 的发生没有相关性（p  = 0.37）。同样，血清 MMP-9 水平与超声血管痉挛 (0.05) 以及出院时改良 Rankin 量表 (mRS) ( p  = 0.27)、3 个月时 mRS ( p  = 0.22) 和格拉斯哥结果之间均不存在相关性。3 个月时量表扩展 (GOSE) ( p  = 0.15)。血清 MMP-9 水平并不能预测 aSAH 后 DCI 的发生。